Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978156 · ClinicalTrials.gov registry record · Phase 1
Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03978156: Clinical Trial Phase 1 study, sponsored by Yale University.
NCT03978156 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03978156, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Primary Outcome
Feasibility will be defined by ability to mask patients and investigators to treatment assignment and adherence which will be defined in 3 ways.
Interventions
- DRUG Dronabinol 2.5 MG
- DRUG Microcrystalline cellulose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-07-26 |
| Est. Completion | 2021-01-01 |
| Phase | Phase 1 |
Why NCT03978156 stopped before completion
NCT03978156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Dronabinol 2.5 MG is the first listed.
NCT03978156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03978156 about?
NCT03978156 is a clinical study titled "Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease". This study is designed to address the feasibility of a randomized, double masked, cross-over study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
What is the current status of trial NCT03978156?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-07-26. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT03978156?
The interventions under investigation include: Dronabinol 2.5 MG (DRUG), Microcrystalline cellulose (DRUG).
Who is sponsoring clinical trial NCT03978156?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03978156's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI